EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A single-cell transcriptomics-based prognostic model identifies TM4SF1 as a key promoter of malignant progression in lung adenocarcinoma

Jiahua Li, Tianci Liu, Ling Li, Weiguo Lu, Junyuan Huang, Xi Li, Yingchun Zhou

Frontiers in Oncology · 06.11.2026 · 16

DOI: 10.3389/fonc.2026.1948068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 06.11.2026. Verfasst von Jiahua Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intratumor heterogeneity in lung adenocarcinoma (LUAD) profoundly influences tumor progression and immune evasion. However, current prognostic models largely fail to capture the complex cellular dynamics of the tumor microenvironment (TME) at single-cell resolution.

Methods

We integrated single-cell RNA sequencing with bulk transcriptomics to derive cell-type-specific signatures. A systematic evaluation of 101 machine learning algorithm combinations was performed across multiple independent cohorts to construct a robust prognostic model. Immune landscape, mutational features, intercellular communication, and immunotherapy responsiveness were comprehensively evaluated. The biological functions of the identified hub gene, transmembrane 4 L six family member 1 (TM4SF1), were rigorously validated in vitro .

Results

The optimal StepCox[forward]-Ridge model showed strong prognostic stratification in five cohorts. Low-risk tumors exhibited an immune-inflamed phenotype, suggesting greater predicted good responses to immune checkpoint blockade. In contrast, high-risk tumors had an immunosuppressive TME with overactive cell communication driven by fibroblasts and myeloid cells. TM4SF1 was a key driver in this high-risk signature. TM4SF1 silencing significantly inhibited LUAD cell proliferation, migration, and invasion, and strongly induced apoptosis. TM4SF1 depletion reversed tumor immune evasion by reducing PD-L1, increasing MHC-I, and lowering the secretion of CCL5.

Conclusions

This single-cell-guided machine-learning framework provides strong prognostic stratification in LUAD and captures immune phenotypes associated with potential immunotherapy responsiveness. TM4SF1 emerged as a candidate mediator associated with malignant progression and immune-related phenotypes in LUAD, warranting further mechanistic and in vivo investigation. This suggests it could be a useful therapeutic target.

Schlagwörter

Stichwörter der Autor:innen

TM4SF1lung adenocarcinomamachine learningsingle-cell transcriptomicstumor microenvironment

Autor:innen und Institutionen

  • The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Department of Medical Laboratory, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Baiyun Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.

Zitieren

APA

Li, J., Liu, T., Li, L., Lu, W., Huang, J., Li, X., & Zhou, Y. (2026). A single-cell transcriptomics-based prognostic model identifies TM4SF1 as a key promoter of malignant progression in lung adenocarcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1948068

Vancouver

Li J, Liu T, Li L, Lu W, Huang J, Li X, et al. A single-cell transcriptomics-based prognostic model identifies TM4SF1 as a key promoter of malignant progression in lung adenocarcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1948068

BibTeX
@article{Li2026,
  author = {Li, Jiahua and Liu, Tianci and Li, Ling and Lu, Weiguo and Huang, Junyuan and Li, Xi and Zhou, Yingchun},
  title = {A single-cell transcriptomics-based prognostic model identifies TM4SF1 as a key promoter of malignant progression in lung adenocarcinoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1948068}
}
Kostenlos starten →